Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Monday, September 26, 2016

PCSK9 Drug Regresses Coronary Plaque

But is it better than watermelon juice or pomegranate juice or coffee or aged garlic extract ? A simple question that will never be answered because we have NO fucking stroke leaders or strategy.

Watermelon juice reverses hardening of the arteries 

Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation 

Regular coffee drinkers have 'cleaner' arteries

New study shows aged garlic extract can reduce dangerous plaque buildup in arteries



PCSK9 Drug Regresses Coronary Plaque 

The PCSK9 inhibitor evolocumab (Repatha) reduces atherosclerosis volume as measured by intravascular ultrasound (IVUS) compared with placebo atop statin therapy, Amgen announced in topline results from the GLAGOV trial.
Along with that positive finding for the primary endpoint at 78 weeks, the trial also met the secondary endpoints of percent and total atheroma volume regression from baseline.
The findings were encouraging, Pablo Corral, MD, a lipid specialist at the Instituto de Clinica Medica in Buenos Aires, and Sekar Kathiresan, MD, of Massachusetts General Hospital in Boston, agreed in a conversation on Twitter.
It might make positive findings more likely from the pending large cardiovascular outcomes trial, due out early in 2017, suggested Ethan Weiss, MD, of the University of California San Francisco, in the same conversation. "Anecdotally, IVUS correctly predicted torcetrapib results," whereas carotid intima-media thickness did not, Weiss added.
However, "I wouldn't declare victory too early," responded Harlan Krumholz, MD, of Yale University in New Haven, Conn., noting that the outcomes trials haven't been stopped prematurely for efficacy.
The phase III GLAGOV trial included 968 patients getting cardiac catheterization, who were on optimized background statin therapy and randomized to double-blind treatment with evolocumab (420 mg monthly) or placebo subcutaneous injections.
Amgen said no new safety concerns emerged in the trial nor was there a difference in treatment-emergent adverse events between groups.
Detailed results are slated for presentation at the American Heart Association meeting in November.term

No comments:

Post a Comment